Scarica l'app Stockscreener
4.17
5.30%
0.21
Pre-mercato:
3.76
-0.41
-9.83%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.96
Aprire:
$3.98
Volume 24 ore:
89,322
Relative Volume:
1.04
Capitalizzazione di mercato:
$151.71M
Reddito:
-
Utile/perdita netta:
$-19.90M
Rapporto P/E:
-7.8679
EPS:
-0.53
Flusso di cassa netto:
$-19.80M
1 W Prestazione:
+17.80%
1M Prestazione:
-15.76%
6M Prestazione:
-3.81%
1 anno Prestazione:
+70.20%
Intervallo 1D:
$3.98
$4.195
Intervallo di 1 settimana:
$3.335
$4.195
Portata 52W:
$2.14
$6.8184
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Nome
Diamedica Therapeutics Inc
Settore
Industria
Telefono
(763) 496-5454
Indirizzo
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Confronta DMAC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
4.17 | 151.71M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.47 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
599.76 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
600.51 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.61 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.16 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-24 | Ripresa | Craig Hallum | Buy |
| 2023-06-22 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-04-09 | Iniziato | Oppenheimer | Outperform |
| 2021-02-17 | Iniziato | ROTH Capital | Buy |
| 2020-10-30 | Iniziato | Guggenheim | Buy |
| 2020-07-08 | Iniziato | Maxim Group | Buy |
| 2019-04-30 | Iniziato | Dougherty & Company | Buy |
| 2019-03-05 | Iniziato | Lake Street | Buy |
Mostra tutto
Diamedica Therapeutics Inc Borsa (DMAC) Ultime notizie
LPL Financial LLC Buys 11,500 Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
Financial Contrast: BioVie (NASDAQ:BIVI) vs. DiaMedica Therapeutics (NASDAQ:DMAC) - Defense World
DiaMedica Therapeutics: Stroke Developer With Low Cash Reserve (NASDAQ:DMAC) - Seeking Alpha
Raymond James Financial Inc. Purchases Shares of 15,267 DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
(DMAC) Trading Report - news.stocktradersdaily.com
DiaMedica Therapeutics (NASDAQ:DMAC) Price Target Raised to $10.00 - Defense World
Equities Analysts Offer Predictions for DMAC Q1 Earnings - Defense World
DiaMedica Therapeutics Reports 2024 Financial Results - TipRanks
DiaMedica Therapeutics Announces Closing of $8.5 Million Public Offering of Common Shares - Business Wire
H.C. Wainwright lifts DiaMedica stock target to $10 on trial hopes - Investing.com Canada
H.C. Wainwright lifts DiaMedica stock target to $10 on trial hopes By Investing.com - Investing.com South Africa
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2024 Earnings Call Transcript - Insider Monkey
DiaMedica Therapeutics Inc (DMAC) Q4 2024 Earnings Call Highlights: Strong Financial Position ... - Yahoo
DiaMedica Therapeutics’ Optimistic Earnings Call Highlights - TipRanks
Earnings call transcript: DiaMedica Q4 2024 results and stock surge By Investing.com - Investing.com South Africa
Earnings call transcript: DiaMedica Q4 2024 results and stock surge - Investing.com India
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results - BioSpace
DiaMedica Therapeutics Reports 2024 Financial Results and Strategic Advancements - TipRanks
DiaMedica Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
DIAMEDICA THERAPEUTICS Earnings Results: $DMAC Reports Quarterly Earnings - Nasdaq
Insider Stock Buying Reaches US$9.00m On DiaMedica Therapeutics - Yahoo Finance
Where are the Opportunities in (DMAC) - Stock Traders Daily
DIAMEDICA THERAPEUTICS Earnings Preview: Recent $DMAC Insider Trading, Hedge Fund Activity, and More - Nasdaq
DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025 - Business Wire
DiaMedica Therapeutics (DMAC) to Release Quarterly Earnings on Tuesday - Defense World
Insiders At DiaMedica Therapeutics See Good Returns After Buying Stock Worth US$9.00m - Simply Wall St
DiaMedica Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
DiaMedica announces board member Richard Pilnik’s retirement - Investing.com
DiaMedica announces board member Richard Pilnik’s retirement By Investing.com - Investing.com South Africa
Trading (DMAC) With Integrated Risk Controls - Stock Traders Daily
Y Intercept Hong Kong Ltd Takes $81,000 Position in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
DiaMedica Therapeutics Appoints Daniel J. O’Connor to Board - MSN
DiaMedica welcomes new board member with biopharma leadershi By Investing.com - Investing.com Nigeria
DiaMedica welcomes new board member with biopharma leadershi - Investing.com
DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors - Business Wire
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Down 8.4% in January - MarketBeat
DiaMedica reports on DM199 stroke treatment mechanism By Investing.com - Investing.com Nigeria
DiaMedica reports on DM199 stroke treatment mechanism - Investing.com
DiaMedica Therapeutics Announces Publication Of Dm199'S Mechanism Of Action For The Treatment Of Acute Ischemic Stroke In The Journal Stroke - Marketscreener.com
DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke - Business Wire
Learn to Evaluate (DMAC) using the Charts - Stock Traders Daily
DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
DiaMedica's Game-Changing Stroke Treatment Takes Center Stage at Major Healthcare Conference (DMAC) - Stock Titan
Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Grows By 14.5% - MarketBeat
DiaMedica Therapeutics (NASDAQ:DMAC) Trading Down 1.5%Here's Why - MarketBeat
Diamedica Therapeutics Inc Azioni (DMAC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Diamedica Therapeutics Inc Azioni (DMAC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Giuffre Randall Michael | Director |
Feb 13 '25 |
Option Exercise |
2.56 |
17,000 |
43,570 |
392,412 |
| Von Koch Thomas | 10% Owner |
Jun 28 '24 |
Buy |
2.50 |
1,200,000 |
3,000,000 |
5,526,435 |
| STAHLBERG JAN | 10% Owner |
Jun 28 '24 |
Buy |
2.50 |
1,200,000 |
3,000,000 |
5,221,608 |
2.04%
2.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):